IDEAS home Printed from https://ideas.repec.org/a/ssi/jouesi/v7y2020i4p3001-3015.html
   My bibliography  Save this article

Impact of innovative activity of organizations on the development of pharmaceutical industry: a case study

Author

Listed:
  • Natalia Leonidovna Borscheva

    (I.M. Sechenov First Moscow State Medical University, Russian Federation)

  • Yulia Vyacheslavovna Fedorova

    (I.M. Sechenov First Moscow State Medical University, Russian Federation)

  • Marina Ivanovna Glukhova

    (I.M. Sechenov First Moscow State Medical University, Russian Federation)

  • Guzal Ilgizovna Islamova

    (I.M. Sechenov First Moscow State Medical University, Russian Federation)

Abstract

Тhe article proposes a new methodological approach to the study and evaluation of external factors affecting innovation activity. External factors were estimated, a correlation model was built, and key factors affecting innovation activity and susceptibility to innovation of Russian companies were identified. A regression model reflecting the dependence of the level of innovation activity of Russian companies on changes in environmental factors in the dynamics from 2006 to 2016 was constructed. The study was conducted on the basis of statistical data on the development of the pharmaceutical industry as one of the high-tech industries of the Russian industry. The study confirmed and measured the relationship between the macro factors of development of the Russian pharmaceutical industry and the volume of its production. This study is an occasion to discuss and further study the development of sound recommendations to change or improve the state industrial policy. Directions of further researches are connected with a deeper study of the causes of interrelation of volume of output and macroeconomic factors, as well as with the assessment of the temporal distribution of the macroeconomic consequences of purposeful influence on the magnitude of the factors considered.

Suggested Citation

  • Natalia Leonidovna Borscheva & Yulia Vyacheslavovna Fedorova & Marina Ivanovna Glukhova & Guzal Ilgizovna Islamova, 2020. "Impact of innovative activity of organizations on the development of pharmaceutical industry: a case study," Entrepreneurship and Sustainability Issues, VsI Entrepreneurship and Sustainability Center, vol. 7(4), pages 3001-3015, June.
    • Handle: RePEc:ssi:jouesi:v:7:y:2020:i:4:p:3001-3015
    DOI: 10.9770/jesi.2020.7.4(29)
    as

    Download full text from publisher

    File URL: https://jssidoi.org/jesi/uploads/articles/28/Borscheva_Impact_of_innovative_activity_of_organizations_on_the_development_of_pharmaceutical_industry_a_case_study.pdf
    Download Restriction: no
    File URL: https://jssidoi.org/jesi/article/568
    Download Restriction: no
    File URL: https://libkey.io/10.9770/jesi.2020.7.4(29)?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016. "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, vol. 47(C), pages 20-33.
    2. repec:ers:journl:v:volumexxi:y:2018:i:issue4:p:502-511 is not listed on IDEAS
    3. Eli Ayawo Atatsi & Jol Stoffers & Ad Kil, 2019. "Factors affecting employee performance: a systematic literature review," Journal of Advances in Management Research, Emerald Group Publishing Limited, vol. 16(3), pages 329-351, February.
    4. A.V. Voloshin & J.J. Suslova & E.A. Batrayeva & L.V. Baguzova & N.V. Ananeva, 2018. "Current State, Tendencies and Peculiarities of Development in Higher Education: The Case of Russia," European Research Studies Journal, European Research Studies Journal, vol. 0(4), pages 502-511.
    5. Brem, Alexander & Nylund, Petra A. & Schuster, Gerd, 2016. "Innovation and de facto standardization: The influence of dominant design on innovative performance, radical innovation, and process innovation," Technovation, Elsevier, vol. 50, pages 79-88.
    6. Gustavo Crespi & Jorge Katz & Jocelyn Olivari, 2018. "Innovation, natural resource-based activities and growth in emerging economies: the formation and role of knowledge-intensive service firms," Innovation and Development, Taylor & Francis Journals, vol. 8(1), pages 79-101, January.
    7. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," CRETA Online Discussion Paper Series 52, Centre for Research in Economic Theory and its Applications CRETA.
    2. Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022. "Generic competition and the incentives for early-stage pharmaceutical innovation," Research Policy, Elsevier, vol. 51(10).
    3. Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Risks, MDPI, vol. 6(3), pages 1-27, July.
    4. Yin, Nina, 2023. "Pharmaceuticals, incremental innovation and market exclusivity," International Journal of Industrial Organization, Elsevier, vol. 87(C).
    5. Camille Loir & Bertrand Groslambert, 2023. "The impact of innovation on the profitability of the biotech industry," Economics Bulletin, AccessEcon, vol. 43(3), pages 1286-1297.
    6. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    7. Lo, Andrew W. & Thakor, Richard T., 2023. "Financial intermediation and the funding of biomedical innovation: A review," Journal of Financial Intermediation, Elsevier, vol. 54(C).
    8. Arisa Djurian & Tomohiro Makino & Yeongjoo Lim & Shintaro Sengoku & Kota Kodama, 2020. "Trends of Business-to-Business Transactions to Develop Innovative Cancer Drugs," Sustainability, MDPI, vol. 12(14), pages 1-14, July.
    9. Manuel Hermosilla, 2021. "Rushed Innovation: Evidence from Drug Licensing," Management Science, INFORMS, vol. 67(1), pages 257-278, January.
    10. Kristopher J. Hult, 2017. "Measuring the Potential Health Impact of Personalized Medicine: Evidence from MS Treatments," NBER Working Papers 23900, National Bureau of Economic Research, Inc.
    11. Fossett, Sarah J. & Wunnava, Phanindra V., 2017. "Active Ingredients: Exploring the Key Factors Affecting the Rising Cost of Developing New Drugs," IZA Discussion Papers 10817, Institute of Labor Economics (IZA).
    12. Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," Research Papers 3889, Stanford University, Graduate School of Business.
    13. Kristopher J. Hult, 2018. "Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 185-216, National Bureau of Economic Research, Inc.
    14. Tobias Basse & Christoph Schwarzbach & J.-Matthias Schulenburg, 2023. "Dividend policy issues in the European pharmaceutical industry: new empirical evidence," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(5), pages 803-816, July.
    15. Benjamin Speich & Nadine Schur & Dmitry Gryaznov & Belinda von Niederhäusern & Lars G Hemkens & Stefan Schandelmaier & Alain Amstutz & Benjamin Kasenda & Christiane Pauli-Magnus & Elena Ojeda-Ruiz & Y, 2019. "Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation," PLOS ONE, Public Library of Science, vol. 14(1), pages 1-16, January.
    16. Paolo Pertile & Simona Gamba & Martin Forster, 2018. "Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence," Discussion Papers 18/04, Department of Economics, University of York.
    17. Gregor Dorfleitner & Felix Rößle, 2018. "The financial performance of the health care industry: a global, regional and industry specific empirical investigation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 585-594, May.
    18. Ralph Siebert & Zhili Tian, 2020. "Dynamic Mergers Effects on R&D Investments and Drug Development across Research Phases in the Pharmaceutical Industry," CESifo Working Paper Series 8303, CESifo.
    19. Sanzenbacher, Geoffrey T. & Wettstein, Gal, 2020. "Drug insurance and the strategic behavior of drug manufacturers: Evergreening and generic entry after Medicare Part D," Journal of Health Economics, Elsevier, vol. 72(C).
    20. Angelo Kenneth S. Romasanta & Peter Sijde & Jacqueline Muijlwijk-Koezen, 2020. "Innovation in pharmaceutical R&D: mapping the research landscape," Scientometrics, Springer;Akadémiai Kiadó, vol. 125(3), pages 1801-1832, December.

    More about this item

    Keywords

    management; innovative activity; innovative development; model; external environment factors; pharmaceutical industry;
    All these keywords.

    JEL classification:

    • O11 - Economic Development, Innovation, Technological Change, and Growth - - Economic Development - - - Macroeconomic Analyses of Economic Development
    • O31 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights - - - Innovation and Invention: Processes and Incentives
    • O32 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights - - - Management of Technological Innovation and R&D

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ssi:jouesi:v:7:y:2020:i:4:p:3001-3015. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Manuela Tvaronaviciene (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.